Rznomics publishes new method to improve circular RNA manufacturing for vaccines, gene therapies
Rznomics Inc., a clinical-stage biopharmaceutical based in Seongnam, South Korea, announced that research published online on 4 September in Nucleic Acids Research describes optimized methods for in vitro production of circular RNA. The peer-reviewed paper details systematic target-site selection an
<p>Rznomics Inc., a clinical-stage biopharmaceutical based in Seongnam, South Korea, announced that research published online on 4 September in Nucleic Acids Research describes optimized methods for in vitro production of circular RNA. The peer-reviewed paper details systematic target-site selection an</p>